Trial Profile
A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- Acronyms HART
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 10 Aug 2023 the protocol has been amended as above-1) phase has been changed from 2/3 to 2 . 2) primary endpoint has been changed.
- 22 Feb 2023 Results of pooled analysis assessing the pridopidine's effect on the QT interval and investigated its cardiac safety profile from NCT02006472, NCT00724048 and NCT00665223 trials, published in the Neurology and Therapy.
- 18 Jun 2015 Pooled safety analysis ( combination with antidepressants or antipsychotics), results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.